Is the Clinical Benefit Rate at Sixteen Weeks a Reliable End Point?
- PMID: 29847293
- DOI: 10.1200/JCO.2018.78.5139
Is the Clinical Benefit Rate at Sixteen Weeks a Reliable End Point?
Comment in
-
Reply to K.S. Shohdy et al.J Clin Oncol. 2018 Aug 10;36(23):2458-2459. doi: 10.1200/JCO.2018.78.8349. Epub 2018 May 30. J Clin Oncol. 2018. PMID: 29847296 No abstract available.
Comment on
-
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.J Clin Oncol. 2018 Mar 20;36(9):884-890. doi: 10.1200/JCO.2016.71.3495. Epub 2018 Jan 26. J Clin Oncol. 2018. PMID: 29373071 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources